


REMARKS

Claims 1, 3, 4 and 20-35 are in the case. The abstract is amended in accordance with the U.S. practice. Claims 3 and 4 are herein amended for editorial purposes. Claims 2 and 5-19 are herein cancelled. New claims 21-35 correspond to cancelled claims 5-19, respectively, but are presented as method claims. No new matter has been introduced.

Consideration of the present application in view of the above amendments is respectfully requested.

Dated: December 13, 2005

Respectfully submitted,

By 
Charles E. Miller
Registration No.: 24,576
DICKSTEIN SHAPIRO MORIN & OSHINSKY
LLP
1177 Avenue of the Americas
New York, New York 10036-2714
(212) 835-1400
Attorney for Applicants

Attachment: A replacement ABSTRACT.

ABSTRACT

GCS-INHIBITING PIPERIDINE DERIVATIVE

The present invention relates to the compound 3,4,5-piperidinetriol, 2-(hydroxymethyl)-1-[(4-(pentyloxy)phenyl)methyl]-, (2S,3S,4R,5S), or a pharmaceutically acceptable salt or prodrug thereof, which is useful as an inhibitor of glucosylceramide synthase. The compounds of the Invention are useful for treating various glycolipid storage diseases, such as Gaucher's disease, Sandhoff's disease, Tay-Sachs disease, Fabry disease, and GM1 gangliosidosis; glycolipid accumulation disorders, such as Niemann-Pick disease, mucopolysaccharidoses, mucopolipidosis type IV and α -mannosidosis; various cancers that involve abnormal glycolipid synthesis; and various infectious diseases that involve cell surface glycolipids as receptors for the infectious organisms or for their toxins; as well as a variety of other disorders involving glycolipid synthesis, including neuronal disorders, inflammatory diseases, obesity, and the like.